Recent CABA News
- Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum • GlobeNewswire Inc. • 07/02/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 10:06:37 AM
- Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201 • GlobeNewswire Inc. • 06/14/2024 06:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 11:27:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 11:17:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:32:55 PM
- Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 11:53:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:04:38 AM
- Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/15/2024 11:00:00 AM
- Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/13/2024 12:00:00 PM
- Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis • GlobeNewswire Inc. • 03/20/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:50:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:45:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:36:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:36:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:28:16 PM
- Cabaletta Bio to Participate in Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:20:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 11:47:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:36:00 PM
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis • GlobeNewswire Inc. • 02/01/2024 09:30:00 PM
- Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 11:30:06 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM